A Phase I Placebo-controlled, Double-blind, Dose Escalation Clinical Trial to Evaluate the Safety and Immune Responses of Imcyse's IMCY-0098 in Patients With Recent Onset Type 1 Diabetes

Imcyse SA17 sites in 7 countries41 target enrollmentStarted: August 23, 2017Last updated: September 6, 2019

ConditionsType 1 Diabetes Mellitus

InterventionsPlacebo IMCY-0098

DrugsIMCY-0098

Overview

Phase: Phase 1
Status: Completed
Sponsor: Imcyse SA
Enrollment: 41
Locations: 17
Primary Endpoint: Incidence of all adverse events reported for subjects

Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Overview

Brief Summary

This clinical study will evaluate the safety of an innovative approach expected to be disease-modifying by stopping the auto-immune-mediated destruction of islet β-cells in the pancreas. Three doses of the investigational product will be tested in successive cohorts. Although safety is the first objective of this study, we will gather efficacy data and perform a set of immunological tests to further understand the mechanism of action of this new approach in young adults with recent onset type 1 diabetes.

Study Design

Study Type: Interventional
Allocation: Randomized
Intervention Model: Sequential
Primary Purpose: Treatment
Masking: Triple (Participant, Care Provider, Investigator)

Masking Description

Double-blind, placebo controlled

Eligibility Criteria

Ages: 18 Years to 30 Years (Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Male or female 18 to 30 years of age
•Initial diagnosis of Type 1 diabetes according to ADA/WHO criteria within the past 6 months
•Insulin requirement, as determined by the investigator
•Presence of at least one autoantibody (GAD65, IA-2, or ZnT8)
•Fasting C-peptide at screening \>0.2 nmol/L and/or stimulated C-peptide ≥ 0,4 nmol/L.
•HLADR3-positive and/or HLADR4-positive
•Willingness to undergo the insulin treatment prescribed by the physician
•Body mass index (BMI) between 17-28 kg/m2 at screening
•Fully informed written consent obtained
•Males with reproductive potential should use barrier method of contraception (condom) from screening up to 90 days after last treatment with investigational product.

Exclusion Criteria

•Ongoing or planned pregnancy during the whole duration of the study or lactation
•Presence of significant medical conditions in particular chronic liver condition, chronic hematological disease, renal dysfunction of grade 2 or more according to the World Health Organization (WHO) Toxicity Scale .
•Has any current signs or symptoms of infection at entry or within 2 weeks of entry or has received intravenous antibiotics within 2 months prior to the first planned administration of the study product
•Has received any live, attenuated vaccine within 3 months prior to the first planned administration of the study product (i.e. oral poliomyelitis vaccine, measles-mumps-rubella vaccine, yellow fever vaccine, Japanese encephalitis vaccine, dengue vaccine, rotavirus vaccine, varicella vaccine, live-attenuated zoster vaccine, Bacillus Calmette-Guérin \[BCG\] vaccine, oral typhoid vaccine)
•History of, or current malignancy (except excised basal cell skin cancer)
•Clinical evidence of a diabetes-related complication that could interfere with patient's participation/completion of study
•Primary or secondary immune deficiency disorders
•Human Immunodeficiency virus (HIV), chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
•Presence at screening of abnormal laboratory values grade 2 or more according to the World Health Organization (WHO) Toxicity Scale
•Anti-diabetic treatments other than insulin in the week prior to first study drug administration